newsfilter
← Latest News
GlobeNewswire·

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI